The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety
Open accessAbstract
This review takes into consideration the principal vaccines developed against the SARS-CoV-2 in this unprecedented period of Covid-19 pandemic. We evaluated the mechanism of action of each vaccine as well as the efficacy, the safety and the storage temperature. In addition, the problem of the dose units, the vaccinal strategy, the activity of alternative compounds such as the monoclonal antibodies and especially the issue of the virus variants were also described in detail. Four vaccines are currently used in Italy: Pfizer-BioNTech mRNA BNT162b2 (Comirnaty) (USA), Moderna mRNA 1273 (USA), Astra-Zeneca ChAdOx1-S (recombinant) viral vector adenovirus belonging to Oxford (UK) and Pomezia (Italy), Janssen (two recombinant viral vector adenoviruses) belonging to Johnson & Johnson (USA). The efficacy of Pfizer and Moderna for preventing disease or severe disease results 95-87.5% and 94.5-100%, respectively. The efficacy of Astra-Zeneca and Janssen is about 70% and 65%, respectively; in the case of Janssen, it depends on the geographical area ranging from 72% to 57%. The problem of the administrated doses (one dose, two doses from the same vaccine or from different vaccines, half dose) is also discussed. The vaccination strategy based on the age group remains the simplest, most transparent and fair criterion. This strategy is also based on accelerating the administration of the vaccines, so that as many subjects as possible can be vaccinated quickly for achieving the "herd immunity". The monoclonal antibodies appeared to be a valid solution for the treatment of Covid-19 disease. Two antibodies (bamlanivimab and etesevimab) have just been approved by the FDA. They could also be used for the infection by virus variants which represent a big problem due to their higher transmissibility and virulence and to their lower response to the vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Emerging coronaviruses: Genome structure, replication, and pathogenesis
Chen, Y., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25681 · Cited by 3,062
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527 · cited 2×
“0018%) were reported among the people who received the vaccine.(43) Frail or old people, those with comorbidities, teachers, and health care personnel are at higher risk for adverse events after vaccination.”
BackgroundThrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Adaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860
Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00234-8 · Cited by 1,747
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · doi:10.1101/2021.02.10.21251247 · Cited by 1,257
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102214 · Cited by 1,257
Voysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00432-3 · Cited by 1,119
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F., Chadwick, D. R., Clark, R., Cosgrove, C., Galloway, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107659 · Cited by 1,085
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
Jara, A., Undurraga, E. A., González, C., Paredes, F., Fontecilla, T., Jara, G., Pizarro, A., Acevedo, J., Leo, K., Leon, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107715 · Cited by 866
New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications
Abdool Karim, S. S., & de Oliveira, T. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2100362 · Cited by 699
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
Krammer, F., Srivastava, K., Alshammary, H., Amoako, A. A., Awawda, M. H., Beach, K. F., Bermúdez-González, M. C., Bielak, D. A., Carreño, J. M., Chernet, R. L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2101667 · Cited by 696
Emary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00628-0 · Cited by 603
Evolution of the COVID-19 vaccine development landscape
Le, T. T., Cramer, J. P., Chen, R., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00151-8 · Cited by 556
Neutralizing Activity of BNT162b2-Elicited Serum
Liu, Y., Liu, J., Xia, H., Zhang, X., Fontes-Garfias, C. R., Swanson, K. A., Cai, H., Sarkar, R., Chen, W., Cutler, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102017 · Cited by 537
Genetic determinants of daytime napping and effects on cardiometabolic health
Dashti, H. S., Daghlas, I., Lane, J. M., Huang, Y., Udler, M. S., Wang, H., Ollila, H. M., Jones, S. E., Kim, J., Wood, A. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20585-3 · Cited by 446
Immunological characteristics govern the transition of COVID-19 to endemicity
Lavine, J. S., Bjornstad, O. N., & Antia, R. (2021) · Science · doi:10.1126/science.abe6522 · Cited by 416
The lightning-fast quest for COVID vaccines — and what it means for other diseases
Ball, P. (2021) · Nature · doi:10.1038/d41586-020-03626-1 · Cited by 390
Sputnik V COVID-19 vaccine candidate appears safe and effective
Jones, I., & Roy, P. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00191-4 · Cited by 379
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
Manisty, C., Otter, A. D., Treibel, T. A., McKnight, Á., Altmann, D. M., Brooks, T., Noursadeghi, M., Boyton, R. J., Semper, A., & Moon, J. C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00501-8 · Cited by 369
Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination
Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., Parker, M. A., & Kim, R. J. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2828 · Cited by 341
Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
Edara, V.-V., Pinsky, B. A., Suthar, M. S., Lai, L., Davis-Gardner, M. E., Floyd, K., Flowers, M. W., Wrammert, J., Hussaini, L., Ciric, C. R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2107799 · Cited by 328
Shimabukuro, T., & Nair, N. (2021) · JAMA · doi:10.1001/jama.2021.0600 · Cited by 325
Not just antibodies: B cells and T cells mediate immunity to COVID-19
Cox, R. J., & Brokstad, K. A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00436-4 · Cited by 290
DNA vaccines against COVID-19: Perspectives and challenges
Silveira, M. M., Moreira, G. M. S. G., & Mendonça, M. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118919 · Cited by 285
Vaccine-associated hypersensitivity
McNeil, M. M., & DeStefano, F. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.12.971 · Cited by 273
COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants
(2021) · doi:10.1038/s41467-021-24285-4 · Cited by 272
Cross-reactive memory T cells and herd immunity to SARS-CoV-2
Lipsitch, M., Grad, Y. H., Sette, A., & Crotty, S. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00460-4 · Cited by 260
Suschak, J. J., Williams, J. A., & Schmaljohn, C. S. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1330236 · Cited by 240
He, Z., Ren, L., Yang, J., Guo, L., Feng, L., Ma, C., Wang, X., Leng, Z., Tong, X., Zhou, W., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00238-5 · Cited by 213
Kumar, S., Nyodu, R., Maurya, V. K., & Saxena, S. K. (2020) · Medical Virology: From Pathogenesis to Disease Control · doi:10.1007/978-981-15-4814-7_3 · Cited by 196
Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits
Ravichandran, S., Coyle, E. M., Klenow, L., Tang, J., Grubbs, G., Liu, S., Wang, T., Golding, H., & Khurana, S. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abc3539 · Cited by 196
COVID-19 Vaccines vs Variants—Determining How Much Immunity Is Enough
Rubin, R. (2021) · JAMA · doi:10.1001/jama.2021.3370 · Cited by 187
Wodi, A. P., Ault, K., Hunter, P., McNally, V., Szilagyi, P. G., & Bernstein, H. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7006a1 · Cited by 175
Immunological memory to SARS-CoV-2 assessed for up to eight months after infectionPreprint
Dan, J., Mateus, J., Kato, Y., Hastie, K., Yu, E., Faliti, C. E., Grifoni, A., Ramirez, S., Haupt, S., Frazier, A., et al. (2020) · bioRxiv · doi:10.1101/2020.11.15.383323 · Cited by 147
Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
Xie, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., Menachery, V. D., Weaver, S., Dormitzer, P. R., et al. (2021) · doi:10.1101/2021.01.07.425740 · Cited by 143
Immunological memory to SARS-CoV-2 assessed for up to eight months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2020) · eScholarship (California Digital Library) · Cited by 122
Engineering Antiviral Vaccines
Zhou, X., Jiang, X., Qu, M., Aninwene, G. E., Jucaud, V., Moon, J. J., Gu, Z., Sun, W., & Khademhosseini, A. (2020) · ACS Nano · doi:10.1021/acsnano.0c06109 · Cited by 72
Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada
VILCHES, T. N., Zhang, K., Exan, R. V., Langley, J. M., & Moghadas, S. M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.058 · Cited by 42
Regulators adopt more orphan drugs
Reardon, S. (2014) · Nature · doi:10.1038/508016a · Cited by 20
Next-generation COVID-19 vaccines: here come the proteins
Blakney, A. K., & McKay, P. F. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00258-0 · Cited by 10
Cited by
Emerging concepts of miRNA therapeutics: from cells to clinic
Diener, C., Keller, A., & Meese, E. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.02.006 · Cited by 971
Trials and Tribulations of MicroRNA Therapeutics
Seyhan, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031469 · Cited by 381
(2022) · doi:10.1371/journal.pone.0266844 · Cited by 28
Metadata
- Authors
- Mascellino, M. T., Di Timoteo, F., De Angelis, M., & Oliva, A.
- Venue
- Infection and Drug Resistance
- Publisher
- Informa UK Limited
- Published
- 2021-08
- Volume
- Volume 14
- Pages
- 3459-3476
- ISSN
- 1178-6973 (ISSN-L)
- OpenAlex
- W3197512904
- Cited by
- 253
- References
- 46
- FWCI
- 17.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.